Opus Genetics Reports $70.1M Cash Runway to 2028, 12-Letter Vision Gain in BEST1 Trial
Opus Genetics reported $45.1 million in cash at year-end plus $25.0 million raised, extending its runway into H1 2028. Early Phase 1/2 BEST1 data showed a 12-letter BCVA gain and 23% central subfield thickness reduction, with full Cohort 1 results due mid-2026.
1. 2025 Financial Results and Cash Position
Opus Genetics ended 2025 with $45.1 million in cash and equivalents and raised $25.0 million through a private placement, bringing total resources to $70.1 million. These funds are expected to support operations into the first half of 2028 under current plans, excluding potential future milestone payments.
2. Positive Phase 1/2 BEST1 Trial Outcomes
In the ongoing Phase 1/2 BIRD-1 trial for BEST1-related retinal disease, the sentinel patient achieved a 12-letter Best Corrected Visual Acuity gain and a 23% reduction in central subfield thickness at three months. No ocular inflammation or dose-limiting toxicities were observed, and full Cohort 1 data are anticipated mid-2026.
3. Pipeline Advances and Upcoming Milestones
Recruitment for the LCA5 Phase 3 trial is underway with dosing expected in H2 2026, and an RDEP application slated for Q1 2026. Preclinical MERTK activities are funded for a clinical trial, while the FDA set an October 17, 2026 PDUFA date for Phentolamine Ophthalmic Solution 0.75% in presbyopia, with topline keratorefractive data due H1 2026.